News Release

extractX Ltd. Announces the Signing of Four Letters of Intent

extractX Ltd. Announces the Signing of Four Letters of Intent

Niagara, ON February 15, 2023

extractX Ltd. (“extractX” or the “Company”), – announced today that they have signed Letters of Intent (“LOI”) for the supply of four mobile extraction laboratories planned for use in biomass extraction of Hemp/cannabis.

extractX has developed strong relationships with three companies active in the global cannabis market. These companies have all signed LOIs with extractX for the supply of an extractX Mobile Lab in their planned EU GMP compliant facilities. The companies include Endopure in Viseu, Portugal; Sunset Trading in Western Cape, South Africa, and Jaguar Falls that has two locations planned in each of Antoquia and Bogota, Colombia.

We are excited about advancing these opportunities, and are working closely with each of these companies to move toward final contract stage, where we can then deliver the extractX world class – pharma grade labs” stated Albert Iannantuono, Co-CEO of extractX Ltd.

About extractX Ltd.

extractX designs, builds, and operates industrial scale self-contained mobile extraction laboratories equipped with the most effective and reliable equipment, allowing for efficient 24/7 operation, and unlimited scalability to meet the demand of any size operation. Built to GPP/GMP/EU GMP standards, extractX purpose builds mobile extraction laboratories to service biomass cultivators and producers wherever and whenever the service is needed, onsite and on demand anywhere in the world.

Forward-Looking Statements

Certain statements contained herein constitute forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends and future operating revenues and expenses. Statements regarding the aforementioned are based on several assumptions and are not to be considered fact. Although extractX Ltd. believes that the statements are reasonable, it can give no assurances that such expectation will prove to be correct. Investors are cautioned that any forward-looking statements made by extractX Ltd. contain no guarantee of future performance and that actual results may differ materially from those set forth in the forward-looking statements. For additional information see the reports filed by the company in its securities filings with applicable securities regulators (currently available at www.sedar.com).

Unless otherwise required by applicable securities laws, extractX Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information contact:

Albert Iannantuono, Co-CEO
extractX Ltd.
1027 South Pelham St Unit 2,
Welland, Ontario, L3C 3E2
Tel: (905) 327-5313
Web site: www.extractx.com

News Release

extractX Ltd. Announces a Request for MCTO

extractX Ltd. Announces a Request for MCTO

Niagara, ON January 28, 2023

extractX Ltd. (“extractX” or the “Company”), – has applied to the CSA regulator on January 31, 2023, for a temporary management cease trade order (an MCTO) as an alternative to a general cease trade order in accordance with National Policy 12-203 Cease Trade Orders for Continuous Disclosure Defaults (NP 12-203).

The issuer has a September 30th financial year end. It is required to file by January 29, 2023 audited annual consolidated financial statements for the year ended September 30, 2022, as required by Part 4 of NI 51-102, management discussion and analysis (MD&A) relating to the audited annual consolidated financial statements, as required by Part 5 of NI 51-102, and CEO and CFO certificates relating to the audited consolidated financial statements, as required by National Instrument 52-109 Certification of Disclosure in Issuers’ Annual and Interim Filings (collectively, the required filings).

The company’s accounting records are ready for audit and the auditors have been supplied draft year-end consolidated financial statements along with supporting working papers. We are waiting for the audit to be completed and the final audited year-end consolidated financial statements to be released after the Audit Committee and the Board of Directors approve them.

We are hopeful that the final audited year-end consolidated financial statements and the corresponding Management and Discussion Analysis will be posted within the next sixty (60) days. All of the Interim quarterly reports were timely filed.

About extractX Ltd.

extractX designs, builds, and operates industrial scale self-contained mobile extraction laboratories equipped with the most effective and reliable equipment, allowing for efficient 24/7 operation, and unlimited scalability to meet the demand of any size operation. Built to GPP/GMP/EU GMP standards, extractX purpose builds mobile extraction laboratories to service biomass cultivators and producers wherever and whenever the service is needed, onsite and on demand anywhere in the world.

Forward-Looking Statements

Certain statements contained herein constitute forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends and future operating revenues and expenses. Statements regarding the aforementioned are based on several assumptions and are not to be considered fact. Although extractX Ltd. believes that the statements are reasonable, it can give no assurances that such expectation will prove to be correct. Investors are cautioned that any forward-looking statements made by extractX Ltd. contain no guarantee of future performance and that actual results may differ materially from those set forth in the forward-looking statements. For additional information see the reports filed by the company in its securities filings with applicable securities regulators (currently available at www.sedar.com).

Unless otherwise required by applicable securities laws, extractX Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information contact:

Albert Iannantuono, Co-CEO
extractX Ltd.
1027 South Pelham St Unit 2,
Welland, Ontario, L3C 3E2
Tel: (905) 327-5313
Web site: www.extractx.com

News Release

Resignation of Chairman of the Board

extractX Ltd. Announces Resignation of Chairman of the Board but will sit on Advisory Board

Niagara, ON January 27, 2023

extractX Ltd. (“extractX” or the “Company”), – announced today that Peter Manuel has resigned from their Board of Directors, his time will be limited as he pursues other opportunities. Peter has been an integral part of the extractX team since joining the company in 2020 and has contributed greatly to the company’s success. He will become part of the Advisory Board and will continue to advise and guide senior staff on strategic objectives.

The ExtractX Board of Directors would like to express their sincere gratitude for Peter’s contributions over the past 2.5 years and wish him the best in his future endeavors.

We would like to thank Peter for his leadership and dedication to extractX. He was instrumental in helping us reach many of our goals. We wish him all the best in his new ventures and are grateful he will still be able to advise.” said CEO Albert Iannantuono.

About extractX Ltd.

extractX designs, builds, and operates industrial scale self-contained mobile extraction laboratories equipped with the most effective and reliable equipment, allowing for efficient 24/7 operation, and unlimited scalability to meet the demand of any size operation. Built to GPP/GMP/EU GMP standards, extractX purpose builds mobile extraction laboratories to service biomass cultivators and producers wherever and whenever the service is needed, onsite and on demand anywhere in the world.

Forward-Looking Statements

Certain statements contained herein constitute forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends and future operating revenues and expenses. Statements regarding the aforementioned are based on several assumptions and are not to be considered fact. Although extractX Ltd. believes that the statements are reasonable, it can give no assurances that such expectation will prove to be correct. Investors are cautioned that any forward-looking statements made by extractX Ltd. contain no guarantee of future performance and that actual results may differ materially from those set forth in the forward-looking statements. For additional information see the reports filed by the company in its securities filings with applicable securities regulators (currently available at www.sedar.com).

Unless otherwise required by applicable securities laws, extractX Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information contact:

Albert Iannantuono, Co-CEO
extractX Ltd.
1027 South Pelham St Unit 2,
Welland, Ontario, L3C 1L7
Tel: (905) 327-5313
Web site: www.extractx.com

News Release

extractX Ltd. Financial Results Q3 2022

extractX Ltd. Announces Financial Results for Its Third Quarter Ended June 30, 2022

Niagara, ON August 26, 2022

extractX Ltd. (“extractX” or the “Company”), today announced financial results for the Company and its subsidiary extractX Incorporated (“EXI”) as at and for the three and nine months ended June 30, 2022. All figures are in Canadian dollars unless otherwise noted.

Q3 2022 Operational Highlights

During the quarter the Company continued to work with its two client partners on extraction activities, as well as accelerated its sales and marketing efforts on a global scale.

The Company reported total contract processing revenue of $344,726 for the nine months ended June 30, 2022 ($241,323 for the nine months ended June 30, 2021). The mobile lab in Kentucky generated $207,159, all in the first three months as the client partner did not process any biomass from January 1, 2022, onwards. Processing is expected to resume when the client partner has satisfactorily reduced their inventory of CBD distillate and has secured more biomass to commerce the extraction process again, most likely in the fourth quarter of 2022. The mobile lab in Thailand became operational in October 2021, however a temporary shortage of acceptable hemp biomass resulted in small test batches being run, thus the contract only generated $28,109 for the six months ended March 31, 2022 ($nil – March 31, 2021). Early in May 2022 the client partner confirmed that they had secured a larger quantity of biomass and resumed processing activities, resulting in the generation of $109,458 of processing revenue in the third quarter.

The Company has also designed a lab to meet EU GMP regulations and standards, which will enable extractX to provide pharmaceutical-grade mobile labs for the pharmaceutical sector. This will be the production model and standard as the Company moves forward. These initiatives were supported in part through a 50% cost sharing grant under the Agricultural Clean Technology Program of the Canadian Government.

The Company’s sales and marketing programs continue to generate qualified leads from around the globe and management is in various stages of discussion and contract negotiations with several parties.

Q3 2022 Financial Highlights

Selected unaudited financial highlights for the three and nine months ended June 30, 2022, and the three and nine months ended June 30, 2021, include the following:

(in $CDN)

3 months

Jun 30 2022

3 months

Jun 30 2021

9 months

Jun 30 2022

9 months

Jun 30 2021

Contract revenue

$109,458

$204,152 $344,726

$241,323

Extraction wages and supplies

45,452

74,641 208,139

173,593

Gross profit

63,916

129,511 136,587

67,730

Expenses
Corporate and operations salaries

97,299

160,961 406,137

468,682

Operating and administrative

365,341

602,363 1,300,398

1,080,066

Amortization of capital assets, net of credits

122,459

72,592 333,463

228,096

585,099

835,916 2,039,998

1,776,844

Net loss before other income and expenses

(521,183)

(706,405) (1,903,411)

(1,709,114)

Other income and expenses

316

40,333 1,603

352,318

Write-off of mobile extraction lab

(532,086)

(532,086)

Cost of reverse takeover acquisition

(1,639,202)

Income tax recovery

21,108

21,108

Net loss for the period

$(520,867)

$(1,177,050) $(3,541,010)

$(1,867,774)

Net comprehensive loss per share

$(0.021)

$(0.051) $(0.143)

$(0.082)

Selected unaudited balance sheet highlights for the three months ended June 30, 2022, and the year ended September 30, 2021, include the following:

 

 

Jun 30

2022

Sep 30

2021

$ $
Total assets
Cash

7,104

1,141,761

Other current assets

597,918

746,434

Capital and other assets

4,297,782

4,523,097

4,902,804

6,411,292

Total long-term liabilities
Deposits on contracts

644,300

828,165

Other current liabilities

763,572

519,361

Deferred contributions

1,024,528

1,084,640

Long term debt

32,880

32,880

2,465,280

2,465,046

Shareholders’ Equity

2,437,524

3,946,246

% of equity in total assets

49.72%

61.55%

Financial Statements

The condensed interim consolidated financial statements of the Company as at and for the three and nine months ended June 30, 2022 and accompanying management’s discussion and analysis have been filed with the securities regulators and are available on SEDAR at www.sedar.com under the Company’s issuer profile.

No stock exchanges have reviewed or accepted responsibility for the adequacy or accuracy of the content of this press release.

About extractX Ltd.

extractX designs, builds, and operates industrial scale self-contained mobile extraction laboratories equipped with the most effective and reliable equipment, allowing for efficient 24/7 operation, and unlimited scalability to meet the demand of any size operation. Built to GPP/GMP/EU GMP standards, extractX purpose builds mobile extraction laboratories to service biomass cultivators and producers wherever and whenever the service is needed, onsite and on demand anywhere in the world.

Forward-Looking Statements

Certain statements contained herein constitute forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends and future operating revenues and expenses. Statements regarding the aforementioned are based on several assumptions and are not to be considered fact. Although extractX Ltd. believes that the statements are reasonable, it can give no assurances that such expectation will prove to be correct. Investors are cautioned that any forward-looking statements made by extractX Ltd. contain no guarantee of future performance and that actual results may differ materially from those set forth in the forward-looking statements. For additional information see the reports filed by the company in its securities filings with applicable securities regulators (currently available at www.sedar.com).

Unless otherwise required by applicable securities laws, extractX Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

News Release

extractX Financial Results Q2 2022

extractX Ltd. Announces Financial Results for Its Second Quarter Ended March 31, 2022

Niagara, ON March 30, 2022

extractX Ltd. (“extractX” or the “Company”), today announced financial results for the Company and its subsidiary extractX Incorporated (“EXI”) as at and for the three and six months ended March 31, 2022. All figures are in Canadian dollars unless otherwise noted.

Q2 2022 Operational Highlights

During the quarter the Company continued to work with its two client partners on extraction activities, as well as accelerated its sales and marketing efforts on a global scale.

The Company reported total contract processing revenue of $235,268 for the six months ended March 31, 2022 ($37,171 for the six months ended March 31, 2021). The mobile lab in Kentucky generated $207,159, all in the first three months as the client partner did not process any biomass from January 1, 2022, on. Processing is expected to resume when the client partner has satisfactorily reduced their inventory of CBD distillate and has secured more biomass to commerce the extraction process again, most likely in the fourth quarter of 2022. The mobile lab in Thailand became operational in October 2021, however a temporary shortage of acceptable hemp biomass resulted in small test batches being run, thus the contract only generated $28,109 for the six months ended March 31, 2022 ($nil – March 31, 2021). Early in May 2022 the client partner confirmed that they had secured a larger quantity of biomass and resumed processing activities.

The Company has also designed a lab to meet EU GMP regulations and standards, which will enable extractX to provide pharmaceutical-grade mobile labs for the pharmaceutical sector. This will be the production model and standard as the Company moves forward. These initiatives were supported in part through a 50% cost sharing grant under the Agricultural Clean Technology Program of the Canadian Government.

The Company’s sales and marketing programs continue to generate qualified leads from around the globe and management is in various stages of discussion and contract negotiations with several parties.

Q2 2022 Financial Highlights

Selected unaudited financial highlights for the three and six months ended March 31, 2022, and the three and six months ended March 31, 2021, include the following:

(in $CDN)

3 months

Mar. 31 2022

3 months

Mar. 31 2021

6 months

Mar. 31

2022

6 months

Mar. 31 2021

Contract revenue

$10,388

$37,171 $235,268

$37,171

Extraction wages and supplies

62,838

60,373 162,597

98,952

Gross profit

(52,450)

(23,202) 72,671

(61,781)

Expenses
Corporate and operations salaries

138,492

178,411 308,838

307,721

Operating and administrative

416,037

269,184 935,057

477,704

Amortization of capital assets, net of credits  

115,318

 

87,804

 

211,004

155,503

669,847

535,399 1,454,899

940,928

Net loss before other income and expenses

(722,297)

(558,601) (1,382,228)

(1,002,709)

Other income and expenses

140

200,396 1,287

311,985

Cost of reverse takeover acquisition

(1,637,202)

Net loss for the period

$(722,157)

$(358,205) $(3,020,143)

$(690,724)

Net comprehensive loss per share

$(0.029)

$(0.016) $(0.122)

$(0.031)

Selected unaudited balance sheet highlights for the three months ended March 31, 2022, and the year ended September 30, 2021, include the following:

 

 

Mar. 31

2022

Sept. 30 2021
$

$

Total assets
Cash

201,595

1,141,761

Other current assets

405,818

746,434

Capital and other assets

4,419,047

4,523,097

5,026,460

6,411,292

Total long-term liabilities
Deposits on contracts

633,900

828,165

Other current liabilities

525,268

519,361

Deferred contributions

1,044,565

1,084,640

Long term debt 32,880 32,880

2,236,613

2,465,046

Shareholders’ Equity

2,789,847

3,946,246

% of equity in total assets

55.50%

61.55%

Financial Statements

The condensed interim consolidated financial statements of the Company as at and for the three and six months ended March 31, 2022 and accompanying management’s discussion and analysis have been filed with the securities regulators and are available on SEDAR at www.sedar.com under the Company’s issuer profile.

No stock exchanges have reviewed or accepted responsibility for the adequacy or accuracy of the content of this press release.

About extractX Ltd.

extractX designs, builds, and operates industrial scale self-contained mobile extraction laboratories equipped with the most effective and reliable equipment, allowing for efficient 24/7 operation, and unlimited scalability to meet the demand of any size operation. Built to GPP/GMP/EU GMP standards, extractX purpose builds mobile extraction laboratories to service biomass cultivators and producers wherever and whenever the service is needed, onsite and on demand anywhere in the world.

Forward-Looking Statements

Certain statements contained herein constitute forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends and future operating revenues and expenses. Statements regarding the aforementioned are based on several assumptions and are not to be considered fact. Although extractX Ltd. believes that the statements are reasonable, it can give no assurances that such expectation will prove to be correct. Investors are cautioned that any forward-looking statements made by extractX Ltd. contain no guarantee of future performance and that actual results may differ materially from those set forth in the forward-looking statements. For additional information see the reports filed by the company in its securities filings with applicable securities regulators (currently available at www.sedar.com).

Unless otherwise required by applicable securities laws, extractX Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

News Release

extractX Financial Results Q1 2022

extractX Ltd. Announces Financial Results for the First Quarter of 2022

Niagara, ON February 28, 2022

extractX Ltd. (“extractX” or the “Company”), today announced financial results for the Company and its subsidiary extractX Incorporated (“EXI”) as at and for the three months ended December 31, 2021. All figures are in Canadian dollars unless otherwise noted.

Q1 2022 Operational Highlights

During the year and following the successful operation and proof-of-concept of the prototype mobile lab, the Company accelerated its sales and marketing efforts on a global scale. As a result of these focused sales and marketing activities, in 2021, the Company entered into two commercial contracts for the provision of mobile extraction labs.

The first contract is for the provision and operation of a mobile extraction lab to a client partner in Franklin, Kentucky. The lab was successfully shipped in March 2021, and the extractX installation team completed the installation and commissioning of the lab within four weeks. The lab was operational shortly thereafter, and successfully processing biomass to distillate. During the first quarter, the mobile lab generated $210,716 of revenue ($nil in Q1 2021). Through the process, the extractX team identified and implemented additional productivity upgrades and operational changes as part of the Company’s continuous improvement program.

The second contract is for the provision of a mobile lab to a client partner in Chiang Mai, Thailand for a three year contract to process CBD from hemp. In mid-July 2021 the mobile lab was shipped from the manufacturing facility in Winnipeg and arrived in Chiang Mai on September 18, 2021. Using the Company’s Installation & Commissioning Guide, as well as support from the extractX team, the team in Thailand were able to get the lab operational within the expected timeframe and this mobile lab started to run the commissioning tests in October 2021 using small batches of biomass during the quarter ended December 31, 2021, generating $14,704 of revenue.

With the Company’s mobile lab deployed and operational in two locations, the Company is now developing the next generation mobile lab, which is expected to provide a substantial increase in biomass throughput over the previous mobile labs. This increase in throughput is expected to be accomplished using the same footprint as previous labs.
The Company is also currently designing an approved lab to meet EU GMP regulations and standards, which will enable extractX to provide pharmaceutical-grade mobile labs for the pharmaceutical sector. This will be the production model and standard as the Company moves forward. These initiatives were supported in part through a 50% cost sharing grant under the Agricultural Clean Technology Program of the Canadian Government.

The Company’s sales and marketing programs continue to generate qualified leads from around the globe and management is in various stages of discussion and contract negotiations with several parties.

Q1 2022 Financial Highlights

Selected financial highlights for the three month periods ended December 31, 2021, and December 31, 2020 include the following:

  Three Months Ended
(in $CDN) Dec 31, 2021

$

Dec 31, 2020

$

     
Contract revenue 224,880
Extraction wages and supplies 99,759 38,579
Gross profit 125,121 (38,579)
Expenses
Corporate and operations salaries 446,968 129,310
Operating and administrative 242,398 208,519
Amortization of capital assets, net of credits 95,686 67,700
785,052 405,529
Net loss before other income and expenses (659,931) (444,108)
Other income and expenses 1,147 111,589
Cost of reverse takeover acquisition (1,639,202)
Net loss for the period (2,297,986) (332,519)
Net comprehensive loss per share (0.093) (0.015)
Total assets
Cash 463,733 1,141,761
Other current assets 506,617 746,434
Capital and other assets 4,511,238 4,523,097
5,481,588 6,411,292
Total long-term liabilities
Deposits on contracts 697,290 828,165
Other current liabilities 354,854 519,361
Deferred contributions 1,064,603 1,084,640
Long term debt 32,504 32,880
2,465,046 2,465,046
Shareholders’ Equity 3,332,337 3,946,246
% of equity in total assets 60.79% 61.55%

Financial Statements

The consolidated financial statements of the Company as at and for the three months ended December 31, 2021 and accompanying management’s discussion and analysis have been filed with the securities regulators and are available on SEDAR at www.sedar.com under the Company’s issuer profile.

No stock exchanges have reviewed or accepted responsibility for the adequacy or accuracy of the content of this press release.

About extractX Ltd.

extractX designs, builds, and operates industrial scale self-contained mobile extraction laboratories equipped with the most effective and reliable equipment, allowing for efficient 24/7 operation, and unlimited scalability to meet the demand of any size operation. Built to GPP/GMP/EU GMP standards, extractX purpose builds mobile extraction laboratories to service biomass cultivators and producers wherever and whenever the service is needed, onsite and on demand anywhere in the world.

Forward-Looking Statements

Certain statements contained herein constitute forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business and financing, business trends and future operating revenues and expenses. Statements regarding the aforementioned are based on several assumptions and are not to be considered fact. Although extractX Ltd. believes that the statements are reasonable, it can give no assurances that such expectation will prove to be correct. Investors are cautioned that any forward-looking statements made by extractX Ltd. contain no guarantee of future performance and that actual results may differ materially from those set forth in the forward-looking statements. For additional information see the reports filed by the company in its securities filings with applicable securities regulators (currently available at www.sedar.com).

Unless otherwise required by applicable securities laws, extractX Ltd. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

News Release

extractX Ltd. Reports AGM Results – February 2022

extractX Ltd. Reports Annual General and Special Meeting Results

Niagara, ON February 17, 2022

extractX Ltd. (“extractX” or the “Company”), is pleased to advise that at the Company’s annual general and special meeting (the “Meeting”) held on February 17, 2022, shareholders of the Company approved all of the items put forth at the Meeting, including:

1. Approval of the acts of the directors and officers of the Company

For

%

Against

%

Approval of past acts

18,292,186

100

0

2. Election of Directors

The following individuals were elected as directors for the ensuing year: Andrew Bailey, Albert Iannantuono, Peter Manuel, Mitchell Osak, and Collin Stone.
The following is a summary of the voting results for the Company’s five directors:

Nominees

For

%

Withheld

%

Andrew Bailey

15,814,452

100

0

Albert Iannantuono

15,814,452

100

0

Peter Manuel

15,814,452

100

0

Mitchell Osak

15,814,452

100

0

Collin Stone

15,814,452

100

0

3. Appointment of Jones & O’Connell LLP Chartered Professional Accountants “Jones O’Connell” as Auditors of the Company

Jones & O’Connell LLP Chartered Professional Accountants were appointed as auditors of the Company at a remuneration to be fixed by the directors.

For % Withheld %
Appointment of Jones O’Connell as Auditors of the Company 15,814,452 100 0

4. Approval of Stock Option Plan

The Company’s existing 10% rolling Stock Option Plan was ratified by shareholders.

For

%

Against

%

Approval of Stock Option Plan

15,814,452

100

0

No stock exchanges have reviewed or accepted responsibility for the adequacy or accuracy of the content of this press release.

About extractX Ltd.

extractX designs, builds, and operates industrial scale self-contained mobile extraction laboratories equipped with the most effective and reliable equipment, allowing for efficient 24/7 operation, and unlimited scalability to meet the demand of any size operation. Built to GPP/GMP/EU GMP standards, extractX purpose builds mobile extraction laboratories to service biomass cultivators and producers wherever and whenever the service is needed, onsite and on demand anywhere in the world.

Partner

Salus Bioceutical (Thailand)

The Power of Global - Pharma-grade extraction

extractX is bringing Pharma-Grade EU GMP-ready mobile extraction labs to the world to help our partners launch in new and emerging markets. Built to the highest global standards required to meet rigorous pharma-grade standards partners are accelerating their growth with the potential to open export opportunities.
Our mobile lab solutions provide:

  • Highest Quality Distillate
  • Exceptional Speed to Market
  • Scalability

View the full length video highlighting our relationship with Salus Thailand and learn more about how our partners are leveraging extractX mobile labs to fuel their rapid growth.

Hear from Our Partner

I’m delighted to share our fantastic experience with extractX, our trusted partner for over 3 years. Their mobile extraction labs are some of the best we’ve ever used—sophisticated, EU-GMP graded, and incredibly reliable.​
Their thorough documentation helped us quickly achieve GMP/PICs certification, demonstrating extractX’s commitment to supporting their clients’ regulatory compliance needs. Whenever we’ve faced technical issues, their team responded promptly, no matter the distance between our operations in Thailand and Canada. This kind of support is rare and truly appreciated.​
The extractX labs are also cost-effective, boosting our production while saving space and investment costs. The comprehensive support we received for installation, training, and process validation has been invaluable. In short, extractX offers state-of-the-art, user-friendly, and scalable solutions. We highly recommend them to any business looking for top-quality extraction and distillation equipment.

Name, Salus Bioceutical (Thailand)

To learn how our partner Salus Bioceutical is leveraging extractX technology for first-mover advantage in Thailand and creating a pharma-grade vertically-integrated company, please contact us.

Blog

Capital: A Barrier to Vertical Integration in the Cannabis Industry

Capital: A Barrier to Vertical Integration in the Cannabis Industry

Capital can get spread too thin and banking rules can make working capital more difficult to access in the Cannabis Industry. You may be aware of SAAS (software-as-a-service) that has transformed the business world and helped reduce the upfront capital investment in software design and hardware. With the rise of vertical integration in Cannabis (mandated in some states) the question arises, ‘How can I raise the capital and expertise required to compete within all levels of the cannabis supply chain’? One possible solution which greatly reduces capital requirements and leverages an expert partner is ‘extraction-as-a-service’.

Let’s start with what vertical integration means in the context of cannabis.  The 4 stages of Vertical Integration in cannabis are often referred to as ‘seed to sale’, including: 

1) Cultivation 

2) Extraction 

3) Product manufacturing 

4) Retail distribution 

To be considered vertically integrated a business needs to own every stage within the supply chain, including for example, growing the biomass, extracting the THC/CBD, formulating and packaging a product, such as gummies, and ensuring the product is distributed legally through properly managed dispensaries according to state rules.  

In some states regulators suggest that vertical integration ensures better oversight and control throughout the supply chain and reduces the risk of unregulated products entering the supply chain at any point.  Yet, regulators in other states ban vertical integration as it reduces competition through barriers to entry and gives a smaller number of industry players too much control. Regardless, vertical integration requirements will raise the cost and complexity of market entry.  

Whether you are a large multi-state operator or a smaller start-up, choosing extraction-as-a-service and bringing in an expert partner to manage the entire extraction process will reduce the cost of capital for extraction and the complexity of operation.  You will receive a fully-tested, fully-managed pharma-grade mobile lab solution into your facility, so that you can focus your capital and expertise on what you do best – cultivation, product formulation or distribution.

To find our more about how extractX partners with you to remove the barriers to vertical integration, click here.

Follow us on social media or sign up for our newsletter for company updates and more content like this.

    Subscribe to*:

    Blog

    Understanding Flavonoids in Cannabis

    What are Flavonoids - Understanding Flavonoids in Cannabis

    What are flavonoids?

    While cannabinoids and terpenes seem to be the main topics of conversation when discussing the remarkable compounds found within cannabis, flavonoids may have taken a back seat. With more than 20 varieties of flavonoids known to exist in cannabis, it’s time to take a closer look.

    Flavonoids are found in a variety of plants, known to affect the pigmentation mainly of flowers for the purpose of attracting pollinators. They also play a role in protecting plants from UV rays, pests, and diseases (learn more here), and anecdotal evidence suggests that they offer antioxidant, antibacterial, antiviral, and anti-inflammatory benefits to humans when consumed.

    Did you Know?

    A study found that the flavonoid derivative of cannabis demonstrated significant therapy potential in the treatment of pancreatic cancer.

    To read more, click here.

    What role do flavonoids play in cannabis?

    First, flavonoids affect the coloration, flavours, and aromas in cannabis. Certain flavonoids are responsible for the deep purple colours found in some cannabis strains, similar to the dark colours evident in berries. Flavonoids are also thought to interact with terpenes in cannabis to influence the odour and flavour of the strain.

    Flavonoids

    Flavonoids are thought to be responsible for the deep purple colours often found in cannabis strains. Image source: unsplash.com

    In addition to their colouring and flavouring properties, flavonoids are considered “pharmacologically active” compounds, which means they are thought to provide medicinal benefits to consumers. Though further research is required to empirically prove how flavonoids interact with terpenes and cannabinoids, and are absorbed by the body, it is thought that they play an important role in the entourage effect – a term used to describe the synergistic nature of the many active compounds found in cannabis, and how they are absorbed through the body’s endocannabinoid system.

    The future of flavonoids

    While we’ve learned a lot about flavonoids in recent years, the general consensus in the cannabis community is that there’s a lot more left to discover about these interesting compounds. Though cannabinoids have taken centre stage in cannabis research, with terpenes playing the supporting role, scientists, industry professionals, and consumers alike are gaining a better understanding of the role flavonoids play in cannabis products. From dried flower to extracts, concentrates, edibles, and vape products, a deeper understanding of these compounds will lead to better recreational and medicinal products, and more benefits to end consumers.

    If you’re a hemp or cannabis cultivator, processor, or product formulator hoping to produce high-quality cannabis distillate, we walk to talk! Our turnkey mobile labs arrive at your facility within 4-6 months and require a $0 lab CAPEX. Please contact us to learn about becoming an extractX partner.

    Follow us on social media or sign up for our newsletter for company updates and more content like this.

      Subscribe to*:

      Skip to content